Engflag

Levosure

Quick links to important sections

Levosure

Levosure_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levosure

Quick Facts

Property Description
Active Ingredient Levofloxacin (S-enantiomer)
Form Oral Tablets, Oral Solution, Injectable Solution
Pharmacological Class Fluoroquinolone Antibiotic (Third-generation)
Common Use Treating systemic bacterial infections
Origin Synthetic Compound

What Type of Medicine is Levosure?

Levosure is the trade name for a synthetic, prescription-only medicine containing the active ingredient Levofloxacin. Levofloxacin is formally classified as a third-generation fluoroquinolone and is utilized as a powerful systemic antibiotic (anti-infective agent). It is a single-ingredient product and is chemically distinct as the pure S-(-)-enantiomer of the drug ofloxacin, a structural feature that contributes to its targeted antibacterial efficacy compared to earlier racemic mixtures. The medicine is clinically recognized for its high potency against a broad spectrum of bacterial pathogens.

Active Ingredient and Available Forms of Levosure

The core component driving the drug's function is Levofloxacin, supplied in preparations designed for systemic absorption. Levosure is manufactured in several core dosage forms including oral tablets and an oral solution for ingestion, along with an injectable solution suitable for intravenous delivery. The availability of both oral and intravenous preparations provides flexibility for healthcare providers, allowing for continuity of treatment across different care settings.

General Purpose: How Levofloxacin Fights Bacteria

The primary therapeutic purpose of Levosure is the rapid and decisive elimination of susceptible bacterial pathogens. Levofloxacin is defined as a bactericidal agent, meaning its primary effect is to directly kill the targeted microorganisms. This mechanism is accomplished by blocking two vital bacterial enzymes—DNA gyrase and Topoisomerase IV—which the pathogen needs to copy and repair its genetic material, thereby causing the swift death of the bacteria.

Regulatory References

  1. Levofloxacin - StatPearls - NCBI Bookshelf

What side effects are possible with Levosure?

Possible side effects and safety information

The safety profile of Levosure (Levofloxacin) is formally defined by regulatory documents, which categorize potential adverse reactions by frequency and affected body system. The most common reactions, noted in at least 3% of patients in clinical data, typically involve the Gastrointestinal Disorders (e.g., nausea, diarrhea, constipation) and Nervous System Disorders (e.g., headache, insomnia, dizziness).

The regulatory label places significant emphasis on a group of serious adverse reactions that can be disabling and potentially irreversible, affecting multiple body systems. These include Tendinitis and Tendon Rupture, Peripheral Neuropathy, and certain Central Nervous System effects (e.g., seizures, confusion, psychotic reactions). Other documented serious events are the exacerbation of Myasthenia Gravis, Aortic Aneurysm and Dissection, and Hepatotoxicity (severe liver injury).

Specific Population-Specific Safety Considerations are detailed in the official prescribing information. Older adults have a documented increased risk for severe tendon disorders and aortic events. Patients with renal impairment or those taking corticosteroids also face a higher risk of tendon rupture. Regulatory documents note that tendon problems can occur as early as 48 hours after starting treatment and up to several months after discontinuation.

Safety-related constraints also advise caution in patients with known risk factors for QT interval prolongation (a heart rhythm disorder) and recommend avoiding the medicine in patients with a history of Myasthenia Gravis.

Overdose and Emergency Response

Overdose and When to Seek Help

Levosure contains the active ingredient levofloxacin, a fluoroquinolone antibiotic. Overdose with levofloxacin, particularly with higher doses, has been linked to distinct symptom clusters primarily affecting the central nervous system (CNS).

Documented Overdose Presentations

Official regulatory information describes the clinical manifestations of overdose as including CNS signs such as: confusion, dizziness, impairment of consciousness, and convulsive seizures.

Physiological systems affected may also include the cardiac system, evidenced by prolongation of the QT interval on an electrocardiogram (ECG), which indicates a risk for a serious, abnormal heart rhythm. Erosions of the gastrointestinal mucosa have also been reported with levofloxacin overdose.

Emergency Actions and Urgent Medical Attention

Immediate medical attention is required for any suspected overdose or if severe symptoms occur. In the event of a substantial acute overdose, the required emergency action is to empty the stomach, typically through gastric lavage.

Following gastric lavage, the patient must be observed closely and given appropriate supportive treatment and hydration to maintain kidney function. Due to the risk of QT prolongation, ECG monitoring is necessary during the observation period. Levofloxacin is not effectively removed from the body by hemodialysis or peritoneal dialysis.

Specific populations, particularly those with existing renal impairment (kidney disease), may be at increased risk of overdose symptoms due to reduced drug clearance.

Therapeutic Uses of Levosure

What Levosure Treats: Main Uses and Benefits

Levosure is commonly used across domains where additional symptomatic support is needed for certain bacterial infections. It is relevant in contexts involving heightened systemic burden, or temporary physiological imbalance, and symptoms related to inflammatory states. It is applied across key categories of conditions presenting with acute or disruptive symptom patterns, including complicated Urinary Tract Infections (UTIs), acute exacerbations of chronic bronchitis, various forms of pneumonia, and certain skin and soft tissue infections (SSTIs).

In clinical settings, this medication is used for managing symptoms that interfere with daily functioning, such as fever, cough, chest discomfort, and deep-seated pain. It helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability.

“It is commonly applied in scenarios where short-term symptomatic assistance is needed to help ease the overall symptom load.”

This supportive approach contributes to improved comfort during symptomatic periods and assists with maintaining functional stability. It may also be part of symptomatic management for highly specific systemic threats like Anthrax post-exposure.

Quick Fact: Relief for Infection-Related Distress

Property Description
Primary Symptom Focus Systemic discomfort, inflammatory signs, and pain
Main Use Scenario Acute, complicated, and deep-seated bacterial infections
Patient Benefit Helps ease symptom burden and supports functional stability

Eligibility and Restrictions for Use

Levosure, associated with the drug levofloxacin, is an antibiotic with strict eligibility criteria defined in official regulatory documents to manage safety risks.

Contraindications and Exclusions

The medicine is contraindicated and must not be used in populations with a known hypersensitivity to levofloxacin or other quinolone antibiotics. Use is also strictly avoided in patients with a history of myasthenia gravis (due to risk of exacerbation) or a history of tendon disorders related to previous quinolone use.

Age and Reproductive Status

Population Category Official Eligibility Status
Pediatric Patients (Under 18) Generally not recommended; use is restricted to specific life-threatening public health indications like anthrax or plague.
Pregnant Women Contraindicated or not recommended due to potential risks, as explicitly stated by regulators.
Breastfeeding Women Not recommended; use is generally avoided as the drug passes into breast milk.

Conditional Use and Restrictions

Patients with renal impairment require an official dose adjustment based on creatinine clearance. Use is cautioned in individuals with predisposing factors for seizures or those who are over 60 years old, have a history of organ transplants, or are taking corticosteroid therapy, as these groups carry a documented increased risk of tendon damage.

What should I know about interactions with other medicines?

Levosure (levofloxacin) has documented interactions categorized by their impact on drug exposure and pharmacodynamic activity, requiring specific restrictions as stated in regulatory documents.

Interactions Affecting Drug Exposure

The absorption of the oral formulation is significantly reduced by products containing multivalent cations, such as antacids (magnesium or aluminum), Sucralfate, Didanosine, and mineral supplements (iron or zinc). To prevent chelation and reduced bioavailability, these must be separated from the oral Levosure dose by at least two hours. Concurrently, the renal clearance of levofloxacin is officially reduced when co-administered with tubular blocking agents like Probenecid or Cimetidine, which increases the drug's systemic exposure. For the injectable solution, co-administration in the same intravenous line with any multivalent cations is prohibited.

Interactions Affecting Drug Activity

Pharmacodynamic interactions involve additive effects and require enhanced monitoring. Co-administration is generally avoided with other medicinal products known to prolong the QT interval (e.g., Class IA and III antiarrhythmics) due to an additive risk of cardiac rhythm disturbances. Caution is necessary when using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Theophylline, as these combinations may contribute to a lowering of the cerebral seizure threshold. Finally, Levosure may augment the anticoagulant effects of Vitamin K Antagonists (e.g., Warfarin), a combination that officially requires close monitoring of coagulation tests (PT/INR) and blood glucose when used with antidiabetic agents.

Mechanism of Action

Mechanism of Action: DNA Gyrase and Topoisomerase IV Inhibition

Levofloxacin, the active component of Levosure, exerts its action as a specific inhibitor targeting two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. These enzymes are crucial for maintaining the structural integrity of the bacterial chromosome, facilitating DNA unwinding, replication, and the final partitioning of genetic material during cell division.

The mechanism proceeds via a bactericidal cascade. Levofloxacin interferes by stabilizing a covalent cleavage complex between the enzyme and the DNA strand. This molecular trapping prevents the enzymes from resealing the cleaved DNA, leading to an overwhelming accumulation of double-strand breaks throughout the bacterial genome. This irreparable genetic damage, coupled with the arrest of cell division, overloads the pathogen's repair capacity, resulting directly in the physiological consequence of cell death.

The drug's action is subject to mechanistic limitations, primarily due to mutations in the target genes (gyrA and parC) that reduce binding affinity, and the presence of bacterial efflux pumps that actively transport Levofloxacin out of the cell, thus restricting the induction of the lethal cascade.

Dosage and Administration Information

How to Use Levosure: Administration Principles and Official Regimens

Levosure (levofloxacin) is administered systematically via two approved routes: oral (tablets or solution) and intravenous (IV) infusion. The availability of both forms supports a transition from IV administration, often used initially in a hospital setting, to oral therapy for continued treatment, a common procedural pattern in clinical practice.

Official Dosing and Frequency

Levosure is typically administered once daily. The specific dose, which ranges from 250 mg to 750 mg, and the required course duration (e.g., 3 to 14 days) are determined by the specific condition being addressed.

Administration Pattern Instruction Details
Frequency Once daily
Oral Intake May be taken with or without food
IV Administration Must be given as a slow infusion over 60 to 90 minutes

Required Dose Adjustments

Official instructions mandate dose adjustments for patients with reduced kidney function. For adult patients with a creatinine clearance (CLcr le 50 mL/min), the starting dose and/or the interval between doses must be modified to prevent drug accumulation. This is a standard procedural step for renally excreted medicines.

Administration Requirements

Patients taking oral tablets must swallow them whole. For intravenous use, the solution must be visually inspected prior to administration and must not be mixed with certain other solutions to maintain proper drug stability and delivery.

Recent Clinical Evidence

Levosure, which contains the active ingredient levofloxacin, is a fluoroquinolone class antibiotic. Clinical studies and systematic reviews provide evidence for its use in treating a wide range of bacterial infections.

Efficacy Across Key Indications

Clinical trials have primarily focused on the effectiveness of levofloxacin in addressing infections in the respiratory tract, urinary tract, and skin. Studies in community-acquired pneumonia (CAP) reported high clinical success rates (often exceeding 90%) and favorability when compared to certain traditional cephalosporin-based therapies. The evidence suggests that levofloxacin is associated with efficacy against common respiratory pathogens, including drug-resistant Streptococcus pneumoniae.

For complicated and uncomplicated urinary tract infections (UTIs) and skin and soft tissue infections, clinical trials have established the antibiotic's efficacy in achieving both clinical cure and microbiological eradication, meaning the elimination of the disease-causing bacteria. Randomized controlled trials have been utilized to compare levofloxacin against other antibiotics, such as ciprofloxacin, demonstrating that the treatments were at least equally effective in certain infection types, with levofloxacin often allowing for a shorter course of therapy in some indications (e.g., 5-day versus 10-day regimens for CAP).

Tolerability and Pharmacokinetics

Across multiple studies, levofloxacin has been generally reported as well-tolerated. Furthermore, research shows that its pharmacokinetics (how the body processes the drug) are favorable, with high bioavailability allowing for interchangeable intravenous (IV) and oral dosing and rapid absorption.

How should Levosure be stored and disposed of?

Levosure (levofloxacin) storage and disposal must strictly adhere to regulatory guidelines to ensure product stability and safety.

Official Storage and Disposal

Detail Regulatory Requirement
Storage Temperature Store at Controlled Room Temperature, 68 F to 77 F (20 C to 25 C).
Protection and Handling Keep in the original, tightly closed container, away from excessive heat, moisture, and direct light. Do not freeze the oral solution.
Child Safety Keep out of the reach of children.
Disposal Instructions Dispose of unused or expired medicine through a drug take-back program. If unavailable, mix the drug with an undesirable substance (e.g., kitty litter) and place it in a closed container for household trash; do not flush the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Levosure found in:

A-Z Index: